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ABSTRACT 1 
A total of 103 (0.7%) of 14,236 Streptococcus pneumoniae isolates collected in four Spanish 2 
hospitals from 1989 to 2003 were resistant to rifampicin (MICs 4-512 µg/ml). Only sixty one 3 
(59.2%) of these isolates were available for molecular characterization. Resistance was 4 
mostly related to HIV-infected adult patients and to children with conjunctivitis. Thirty six 5 
different pulse-field gel-electrophoresis patterns were identified among resistant isolates, 6 
five of which were related to international clones (Spain23F-1, Spain6B-2, Spain9V-3, Spain14-7 
5 and clone C of serotype 19F) and accounted for 49.2% of resistant isolates. Single sense 8 
mutations at cluster N or I of the rpoB gene were found in 39 isolates, while double 9 
mutations, either at cluster I, at cluster I and II or at cluster N and III were found in 14 10 
isolates. The involvement of the mutations in rifampicin resistance was confirmed by 11 
genetic transformation. Single mutations at cluster N and I conferred MICs of 2 µg/ml and 12 
4-32 µg/ml, respectively. Eight isolates showed high nucleotide sequence variations (2.3 to 13 
10.8%) in rpoB, suggesting a recombinational origin for these isolates, being viridans 14 
streptococci potential gene donors. Although the majority of rifampicin-resistant isolates 15 
were isolated from individual patients without temporal or geographical relationship, 16 
clonal dissemination of rifampicin-resistant isolates was observed among 12 HIV-infected 17 




Global increase in resistance of Streptococcus pneumoniae to penicillin and multiple 2 
antibacterial agents has emerged worldwide in the 1980s and 1990s severely complicating the 3 
treatment of pneumococcal infections (12, 17, 20, 23, 25). The use of rifampicin (RIF) combined 4 
with either ß-lactams or vancomycine is recommended for the treatment of meningitis caused by 5 
multiresistant pneumococcal isolates (5, 26, 33). The rates of RIF resistance among pneumococci 6 
are low and range from 0.1% in the United States (12), to 0.4% in Spain (23) and to 1.4% in Italy 7 
(25). RIF resistance is usually preceded by RIF therapy, either for tuberculosis (18) or for 8 
prophylaxis or treatment of multidrug resistant pneumococci (36, 38). RIF is also used, in 9 
combined therapy, to treat staphylococcal infections, and it is extensively used in the prophylaxis 10 
of Neisseria meningitidis  exposure. 11 
The bactericidal properties of RIF are due to its high-affinity to bind the bacterial DNA-12 
dependent RNA polymerase and inhibit its function (6), which is essential for bacterial growth 13 
(21). Structural and biochemical studies of the essential catalytic core of the RNA polymerase 14 
(subunit composition α2ββ’ω) of Thermus aquaticus have revealed that RIF interacts with a 15 
pocket of the RNA polymerase β subunit within the DNA-RNA channel and blocks the path of 16 
the elongating RNA when the transcript becomes two or three nucleotides long (6, 40). RIF-17 
resistance has been described in Gram positive and Gram negative bacteria. The mutations 18 
responsible for this phenotype are localized in highly conserved regions, termed clusters N, I, II 19 
and III, of the rpoB gene encoding the β subunit, (6) (Fig. 1). Residues involved in RIF-20 
resistance in several bacteria (2, 3, 9, 19, 31) form part of the RIF binding pocket and twelve of 21 
these residues interact directly with the RIF molecule (6). Few studies describing RIF-resistant 22 
pneumococcal clinical isolates have been reported (7, 15, 29, 32, 38), and all the mutations 23 
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identified were localized in clusters N, I and II. In this study we report the epidemiological and 1 
molecular characteristics of sixty-one RIF-resistant S. pneumoniae clinical isolates collected 2 
during a 15 year period (1989 to 2003) in four Spanish hospitals. 3 
 4 
MATERIALS AND METHODS 5 
 Bacterial isolates and susceptibility tests. Identification was according to standard 6 
methodology and serotypes were determined by a quellung reaction. MICs of penicillin, 7 
erythromycin, clindamycin, tetracycline, chloramphenicol, cotrimoxazole and RIF were 8 
determined by the microdilution method (Sensititre commercial plates) according to the National 9 
Committee for Clinical Laboratory Standards (NCCLS) methods (30). Rifampicin MICs of 10 
transformants were determined by microdilution (30) and by a macrodilution method (1), using a 11 
casein hydrolysate-based medium with 0.2% sucrose (AGCH) (22). S. pneumoniae ATCC 49619 12 
and S. pneumoniae R6 strains were used for the quality control. 13 
 Genetic transformation. S. pneumoniae strain R6 was grown in AGCH and used as 14 
recipient in transformation experiments performed as described (27). Two DNA fragments were 15 
used as donors: a 1,662 bp fragment (RpoB residues M1-L554, taking the first residue of RpoB 16 
as residue number 1) and a 1,038 bp fragment (RpoB residues A428-M773). These fragments 17 
were obtained by PCR amplification from the RIF-resistant isolates and from R6, which was used 18 
as a control. Colonies were counted after 24 h growth at 37 ºC in a 5% CO2 atmosphere in AGCH 19 
medium with 1% agar containing 1 µg/ml of RIF.  20 
 Pulsed-field-gel-electrophoresis (PFGE) and multilocus sequence typing (MLST). 21 
Genomic DNA embedded in agarose plugs was digested with SmaI, and fragments were 22 
separated by PFGE (28). PFGE patterns were compared to 26 representative international clones 23 
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of Pneumococcal Molecular Epidemiology Network (28). Isolates with patterns varying by three 1 
or less bands were considered to represent the same PFGE type (37). MLST was carried out (14) 2 
in one representative RIF-resistant isolate of each dominant PFGE pattern.  3 
 PCR amplification and DNA sequence determination. The RpoB L1-M773 region, was 4 
amplified with oligonucleotides rpob1 (5’-TTGACAAGGCTTGGAACTTAT-3’) and rpob773R 5 
(5’-GTCATGTAGGCAACGAATTGGG-3’). To amplify the 1,662 bp and the 1,038 bp 6 
fragments used in transformation experiments, oligonucleotides rpob1 and rpob554R (5’-7 
CAAGTGTCCGTAAGATGACAAG-3’), and rpob428 (5’-8 
CGGTTGGTGAATTGCTTGCCAACCA-3’) and rpob773R were used, respectively. 9 
Amplifications were performed using 0.5 U of Thermus thermophilus thermostable DNA 10 
polymerase (Biotools, Madrid, Spain), 0.1 µg of chromosomal DNA, 1 µM (each) of the 11 
synthetic oligonucleotide primers, 0.2 mM of each deoxynucleoside triphosphate (dNTP) in the 12 
buffer recommended by the manufacturers. Amplification was achieved with an initial cycle of 1 13 
min denaturation at 94ºC; 25 cycles of 30 s at 94ºC, 45 s at 55ºC and 90 s or 180 s polymerase 14 
extension step at 72ºC; and a final 3-min 72ºC extension step. PCR fragments were purified using 15 
MicroSpin S400 HR columns (Amersham Pharmacia Biotech, Pistcatway, NJ) and sequenced, 16 
using the oligonucleotides used in PCR experiments and internal primers, with an Applied 17 
Biosystems Prism 377 DNA sequencer, accordingly to protocols provided by the manufacturer.  18 
 Nucleotide sequence accession numbers. Sequences submitted to GeneBank were assigned 19 
with the following accession numbers: AY695455 to AY695495, AY695497 to AY695516 and 20 
AY785246 (RIF resistant isolates); AY695496 (Streptococcus  oralis ATCC 10557); AY785247 21 
( S. oralis NCTC 11427). 22 
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RESULTS AND DISCUSSION 1 
 Epidemiological characterization of S. pneumoniae isolates. The overall prevalence of 2 
RIF-resistance among 14,236 pneumococci isolated from clinical specimens in four Spanish 3 
hospitals from 1989 to 2003, was 0,7% (103 isolates with  MICs ≥4µg/ml). However, 4 
geographical variations in resistance rates were found: 0.3% in Hospital Central de Asturias 5 
(HCA) in the North West of Spain, 0.4% in Hospital Universitario de Bellvitge (HUB) in the 6 
North East of Spain (Barcelona), 1.1% in Hospital Gregorio Marañón (HGM) in the Central part 7 
of Spain (Madrid), and 1.1% in Hospital de Donostia (HD) in the North of Spain (Guipuzcoa). 8 
The frequency of RIF-resistant isolates in each hospital from 1989 to 2003 is shown in Fig. 2. 9 
Two hospitals, HCA and HUB, presented low rates during the study period (0-1.1%) whereas HD 10 
and HGM had higher rates, 6% in the 1993-94 period and 3.2% in the 1995-96 period. These 11 
increases of resistance were associated to a dissemination of four RIF-resistant clones among 12 
HIV-infected patients in HD and HGM. From 1999 to 2003 the rates of RIF resistance were 13 
lower than 1.1% in the four hospitals (Fig.2). 14 
Only sixty-one (59.2%) out of 103 RIF-resistant isolates (one per patient) were recovered for 15 
further studies from the stock cultures, accounting for more than 50% of RIF-resistant isolates 16 
collected annually in each hospital. Among the 61 RIF-resistant isolates studied, 47 were isolated 17 
from adults (21-76 years) and 14 from children (<15 years). The sources of the isolates from 18 
adults were: sputum (n = 28), conjunctiva swab (n = 1), blood (n = 11), pleural fluid (n = 2), 19 
broncho-alveolar fluid (n = 2), catheter protected brush specimen (n = 1), pus (n = 1) and ascitic 20 
fluid (n = 1). The majority of pediatric isolates (12 of 14) were from children with conjunctivitis 21 
younger than 1 year-old, and the remaining two isolates were from the blood of an 8 year-old 22 
HIV-infected girl and from conjunctivitis in a 14 year-old child. More than half (32 of 61, 52.4%) 23 
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of RIF-resistant isolates were from HIV-infected adult patients. Moreover, the majority of 1 
invasive isolates (15 of 19, 79.0%) and isolates from sputum  (18 of 28, 64.3%) were also from 2 
HIV-infected patients.  3 
 The in vitro activity of seven antimicrobial agents against the 61 RIF-resistant isolates was 4 
determined and the results are summarized in Table 1. Forty seven (77.1%) isolates were resistant 5 
to penicillin (29 intermediate resistant and 18 resistant) and thirty (49.2 %) were erythromycin 6 
resistant. Multi-drug resistance (resistance to 3 or more chemically unrelated drugs) was detected in 7 
forty-one isolates (67.2%) and 14 of them were resistant to 6 drugs (penicillin, erythromycin, 8 
clindamycin, tetracycline, chloramphenicol and co-trimoxazole). Eight of the RIF-resistant isolates 9 
(13.1%) were susceptible to the other six antibiotics studied. 10 
Next the serotype of the 61 RIF-resistant isolates was determined. Eighteen different 11 
serotypes were identified with the following distribution: 6B (12 isolates), 23F (11 isolates), 14 12 
(8 isolates), 19F (6 isolates), 11 (4 isolates), 6A (3 isolates), 4 (2 isolates), 9N (2 isolates), 9V (2 13 
isolates), and one isolate of each of the remaining serotypes (3, 7F, 15F, 18C, 20, 21, 23A, 31, 14 
and 34). Two isolates were non-typable.  15 
The 61 RIF-resistant isolates were also characterized by their PFGE pattern. A total of 36 16 
different PFGE patterns were identified, 5 PFGE patterns accounted for 30 (49.2%) isolates: 17 
Spain23F-1 (11 isolates), Spain6B-2 (9 isolates), Spain9V-3 (2 isolates), Spain14-5 (2 isolates) and 18 
clone C of serotype 19F (6 isolates). These four international multiresistant epidemic clones have 19 
been common in Spain since the 1980s (8, 16, 34). The association between PFGE patterns and 20 
global international clones (28) was confirmed by multilocus sequence typing (MLST) of one 21 
representative isolate of each PFGE listed in Table 2: Rif-36 (Spain23F-1) had sequence typing 22 
(ST) ST81; Rif-19 (Spain6B-2) had ST90; Rif-55 (Spain9V-3) had ST156; Rif-15 (Spain14-5) had 23 
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ST17 that is a single locus variant of the reference isolate; and Rif-3 (clone C of serotype 19F) 1 
had a ST89. Clone C of serotype 19F (ST89) has been identified in Spain among isolates from 2 
meningitis (16) and among ciprofloxacin-resistant isolates (10), and it has also been found 3 
sporadically in Italy (11) and Denmark (http://www.mlst.net). 4 
 In general, those isolates that shared the same PFGE pattern have the same rpoB 5 
polymorphisms with respect to the reference sequence of strain R6 (Table 2). However, there were 6 
four exceptions: two isolates with rpoB mosaic genes (Rif-13 of the Spain6B-2 clone and Rif-31 of 7 
clone C of serotype 19F); one isolate (Rif-40 of Spain6B-2 clone) which had those polymorphisms 8 
corresponding to the Spain23F-1 clone; and one isolate (Rif-75 of the Spain23F-1 clone) with an 9 
additional polymorphism at codon S498.  10 
 Twelve RIF-resistant isolates were isolated from twelve HIV-infected patients, and grouped in 11 
four clusters (Table 2). One cluster included 5 isolates of the Spain23F-1 clone (Rif-34, -35, -36, -38 12 
and -39) isolated from invasive samples in HGM (Madrid) in 1996. The characteristics of these 13 
isolates and the presence of two amino acid changes in RpoB (M488I, H499Y) suggest a cross-14 
transmission of RIF-resistant pneumococci among HIV-infected patients. The remaining three 15 
clusters were identified at HD (Guipuzcoa) from 1993 to 1995 and included two isolates of the 16 
Spain23F-1 clone (Rif-14 and -22); 3 isolates of Spain6B-2 clone (Rif-18, -19  and -30), and 2 17 
isolates of the Spain14-5 clone (Rif-15 and -16). Temporal or geographical relationship could not be 18 
found among the remaining isolates, suggesting that RIF-resistance among pneumococci is mainly 19 
a sporadic event that occurs in individual patients. 20 
  21 
 Mapping of mutations involved in RIF-resistance. Two RpoB regions: L42-V175 (including 22 
cluster N) and region Q464-T700 (including clusters I, II and III) were sequenced (Fig. 1). 23 
 10
Nucleotide sequence comparisons of the Q464-T700 region among RIF-resistant isolates and R6 1 
revealed 53 isolates with low nucleotide sequence variations (≤0.7%), and 8 with high nucleotide 2 
sequence variations (2.0 to 10.9%). Among the 53 isolates with low variation, 39 had single sense 3 
mutations and 14 double sense mutations (Table 3). Single mutations would produce amino acid 4 
changes at cluster N (Q150) or cluster I (S481, S482, Q486, D489, S495, H499 or L506)(Fig. 1). 5 
The only amino acid change found at cluster N was Q150R, which is involved in low-level 6 
resistance as it has been reported before (29). Twelve residues of clusters I and II (shadowed in Fig. 7 
1) that are conserved in pneumococci and in other bacteria, are directly involved in the interaction 8 
with RIF in the T. aquaticus enzyme (6). Most RIF-resistant isolates had changes at 5 of these 9 
residues (Q486, D489, H499, R501, and L506, Table 3). Position H499 was the most frequently 10 
affected (26 of 39 single mutants), as previously found in pneumococci, either clinical isolates (15, 11 
32) or laboratory mutants (27), as well as in other bacteria (2, 3, 9, 19, 31). The prevalence of 12 
substitutions at H499 could be due to the low biological cost imposed by the presence of changes at 13 
this residue, as has been reported for the H499N change in S. aureus (39) and for the H499Y 14 
change in S. aureus (39) and E. coli (35). Isolates with the highest MICs (128 µg/ml) carried 15 
Q486L, D489V or H499Y changes (Table 3). Two of the single changes, L506S, and H499S, have 16 
not been reported before. Double mutations would produce changes at one residue of cluster N and 17 
one residue of cluster III (isolate Rif-52, see below), two residues of cluster I, or one residue of 18 
cluster I plus a residue of cluster II (Table 3). Although S481, S482, S485, M488, S495, and P537 19 
may not be in direct contact with the RIF molecule (Fig. 1), these residues are located in the 20 
vicinity of the RIF-binding pocket. Alteration of these residues may modify the conformation of the 21 
pocket and consequently, the binding of the antibiotic.  22 
 To establish the contribution of the mutations identified above to RIF resistance, genetic 23 
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transformation experiments were performed. PCR products from the RIF-resistant isolates were 1 
able to transform the susceptible R6 strain (MIC 0.015 µg/ml) to resistance at high frequency 2 
(about 1 × 10-2) whereas PCR products from R6 transformed at frequencies 103-fold lower (about 2 3 
× 10-5). Transformants containing single mutations had MICs equivalent to that of the 4 
corresponding isolate, with a one- or two-fold dilution margin (Table 3). The Q150R change at 5 
cluster N conferred a MIC of 2 µg/ml (TQ150R/Rif-42), equivalent to the MIC of 4-8 µg/ml for the 6 
clinical isolates carrying the same mutation (Rif-42, -52, -61 and -67). Although Rif-52 carried the 7 
Q150R change plus the V638G change at cluster III, no RIF-resistant transformants with PCR 8 
products carrying V638G were obtained. Moreover, since the MIC of TQ150R/Rif-42 is equivalent to 9 
that of Rif-52, it could be assumed that V638G is not involved in RIF resistance. On the other hand, 10 
single mutations at cluster I conferred MICs 4-32 µg/ml (Table 3). To determine the contribution of 11 
the double mutations to resistance, the MICs for transformants containing one or two mutations 12 
were compared (Table 3). These comparisons confirmed the contribution of S485P, M488I and 13 
L506V to resistance: MIC of TS481P, S485P/Rif-59 was 8-fold higher than that of TS481P/Rif-59; MIC of 14 
TM488I, H499Y/Rif-34 was 8-fold higher than that of TH499Y/Rif-12. However, the N547S and D489G 15 
changes would not be involved in resistance given that MIC for TH499Y, N547S/Rif-11 was 2-fold higher 16 
than that for TH499Y/Rif-12, and MIC of TD489G, L506V/Rif-18 was equal than that for TL506V/Rif-18. On the 17 
other hand, the contribution of  D489N, R501H, P537S to RIF-resistance could not be discerned, 18 
since no transformants with those single changes were obtained (Table 3). 19 
 Furthermore, the deduced amino acid sequences of the 8 RIF-resistant recombinant isolates 20 
contained several additional changes, besides the H499N and D489V changes involved in 21 
resistance (Fig. 3B). All recombinant isolates, except Rif-65, share the Y589F change present in 22 
Streptococcus mitis NCTC 12261 and S. oralis NCTC 11427 and S. oralis ATCC 10557 RIF-23 
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susceptible isolates (Fig. 3B), indicating that this residue is not involved in resistance. Likewise, 1 
the I624V, Q671K, N623E, and N669D changes would not be implicated in resistance since they 2 
are also present in RIF-susceptible S. mitis and/or S. oralis strains. However, although it is not 3 
possible to assign the contribution of each residue to resistance, the comparison of the RIF MICs 4 
conferred by the D489V and H499N changes to the non-recombinant pneumococcal isolates (Table 5 
3), suggest that these mutations are indeed responsible for the RIF-resistance phenotypes of the 6 
recombinant isolates.  7 
 Phylogeny of isolates with high nucleotide sequence variation. As pointed out above, a 8 
majority (86.9%) of RIF-resistant isolates showed low-level nucleotide sequence variation (≤ 9 
0.7%) at their Q464-T700 rpoB sequences with respect to strain R6. Similar intraspecific variations 10 
have been determined for atpC-atpA (<0.7%) and for the quinolone-resistance determining regions 11 
of parC, parE gyrA and gyrB (≤1%) (4). However, 8 RIF-resistant isolates showed high nucleotide 12 
sequence variation (2.0-10.9% in the Q464-T700 fragment and 2.3-10.8 in the L42-T700 13 
fragment). The existence of S. pneumoniae RIF-resistant isolates with high nucleotide sequence 14 
variations have been previously described (7, 15, 32). This variation was in accordance with the 15 
divergence found between S. pneumoniae and S. oralis for the amylomaltase gene (4-6%) (13) and 16 
between S. pneumoniae and viridans group streptococci for the parE gene (≥ 8.5%) (4). High 17 
nucleotide sequence variations (Fig. 3) suggested that these isolates would have a mosaic structure 18 
in rpoB as a consequence of recombination with viridans group streptococci. To establish the 19 
mosaic structure, a 1,977-bp region (residues L42-T700) was sequenced and compared with that 20 
from R6. Five isolates (Rif-13, -15, 16, -25, and -56) showed a continuous block of divergence, 21 
suggesting that the recombination points are located outside the region analyzed (Fig. 4). Isolates 22 
Rif-24 and Rif-65 showed two blocks whereas isolate Rif-31 showed three blocks. The blocks with 23 
 13
divergence lower than 1% could represent the recombination sites. 1 
To establish the origin of the gene donor to the Rif-65 isolate (the isolate showing the highest 2 
divergence with respect R6 strain, 10.8%), several WU-Blast2 analysis of the EMBL database 3 
using  were performed. The sequences more similar to rpoB Rif-65 were chosen to perform a 4 
phylogenetic analysis. Since the block structure of the rpoB genes revealed a common variable 5 
region of 357 bp (A474-A592) for the 8 recombinant isolates (Fig. 4A), this fragment was used 6 
for the detection of different clusters within the isolates. All recombinant isolates, except Rif-65, 7 
formed a monophyletic group including S. pneumoniae and viridans streptococcal (S. oralis and 8 
S. mitis) strains (Fig. 4B). These results suggest that the donors in the horizontal transfer of rpoB 9 
genes to S. pneumoniae are the viridans streptococci belonging to S. mitis or S. oralis species, as 10 
described for the penicillin- and fluoroquinolone -resistance determinants (10, 13). Three of these 11 
recombinant isolates belonged to the Spain14-5 and Spain6B-2 clones (Table 2), suggesting a 12 
possible dissemination of RIF-resistance through these clones.  13 
In conclusion, the incidence of RIF-resistance among S. pneumoniae isolates is rare in Spain 14 
and was mainly related to HIV-infected patients and children with conjunctivitis, suggesting a 15 
prior treatment with this drug. Although cross-transmission of RIF-resistant isolates was 16 
demonstrated among HIV-infected patients, the majority of RIF-resistant isolates were isolated 17 
from individual patients without temporal or geographical relationship. This resistance was 18 
acquired either by point mutation in rpoB gene or by recombination with viridans group 19 
streptococci. Continuous surveillance of resistance to rifampicin among invasive pneumococci is 20 
important, because in serious pneumococcal infections a combination of rifampicin and third 21 
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FlGURE LEGENDS 1 
FIG. 1. Regions of S. pneumoniae RpoB and mutations conferring RIF-resistance. RpoB is 2 
represented as a bar showing clusters N, I, II and III (black boxes) and sequenced regions 3 
(stripped area). PCR fragments used for transformations (black bars) and primers (black arrows) 4 
are indicated above. Amino acids that constitute clusters N, I and II of S. pneumoniae (SPN), 5 
Staphylococcus aureus (SAU), Mycobacterium tuberculosis (MTB), Escherichia coli (ECO), and 6 
T. aquaticus (TAQ) are indicated. Amino acid changes found in resistant isolates are shown 7 
above the S. pneumoniae sequence, identical residues are indicated with a star below the T. 8 
aquaticus sequence, residues that changed in RIF-resistant isolates are underlined, the 12 9 
residues involved in RIF binding are shadowed. 10 
FIG. 2. Frequencies of RIF-resistant isolates in four hospitals during the 1989-2003 period. HD, 11 
hospital Donostia (n = 4211); HUB, Hospital Universitario de Bellvitge (n = 5381): HCA, 12 
Hospital Central de Asturias (n = 1056); HGM, Hospital Gregorio Marañón (n = 3588).  13 
FIG. 3. Nucleotide (A) and amino acid (B) sequence variations at RpoB T464-T700 region of 14 
RIF-resistant recombinant isolates. The nucleotides and amino acids present at each polymorphic 15 
site are shown in full for the R6 strain, but for the other isolates, only sites that differ from those 16 
of R6 are shown. Codon numbers are indicated vertically above the sequences. Positions 1, 2, and 17 
3 refer to the first, second, and third nucleotides in the codon, respectively. Sense mutations and a 18 
amino acid changes involved in RIF-resistance are showed in boldface and underlined. 19 
Nucleotides of clusters I, II and III are shadowed. SPN R6, S. pneumoniae R6;  SMI 12261, S. 20 
mitis NCTC 12261; SOR 10557, S. oralis ATCC 10557; SOR 11427, S. oralis NCTC 11427.  21 
FIG. 4. The pneumococcal recombinant isolates interchanged parts of their rpoB genes with 22 
viridans streptococci. (A) Mosaic structure of a 1,977-bp region (L42-T700) of rpoB. The 23 
 21
divergence of each block with respect the R6 sequence is indicated. (B) Phylogenetic tree of a 1 
357-bp region including RpoB residues A474-A592 in which all isolates showed nucleotide 2 
sequence variations in the 4%-9% range. Phylogenetic and molecular evolutionary analysis were 3 
conducted with the MEGA program (version 2.1) by the Neighbor-Joining method. Only 4 
bootstrap confidence intervals exceeding 90% are shown. 5 
 22
TABLE 1. In vitro activity of 7 antimicrobial drugs against 61 rifampicin-resistant Streptococcus 1 










%S %I %R %I+R 
Penicillin 0.5 2 0.03-8 ≤0.06 22.9 47.5 29.5 77.1 
Erythromycin 0.06 ≥256 0.06-≥256 ≤0.25 50.8 0 49.2 49.2 
Clindamycin 0.06 ≥256 0.06-≥256 ≤0.25 52.5 0 47.5 47.5 
Tetracycline 16 64 0.12-64 ≤2 34.4 0 65.6 65.6 
Chloramphenicol 4 16 2-32 ≤4 56.4 0 43.6 43.6 
Cotrimoxazole ≥4/76 ≥4/76 0.5/9.5-≥4/76 ≤0.5/9.5 32.2 1.6 66.1 67.7 
Rifampicin 32 512 4- 512 ≤1 0 0 100 100 
 3 
a S, susceptible; I, intermediate; and R, resistant, according to National Committee for Clinical 4 
Laboratory Standards (NCCLS) 2004 interpretative criteria. 5 
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TABLE 2. Summary of phenotypic characteristics and changes in RpoB among the most 1 
prevalent RIF-resistant pneumococcal clones 2 
 3 
PFGEa  Isolate Sero-
type 
Siteb Year Originc Resistance 
pattern d 




Spain23F-1 Rif-7 23F HD 1991 Sputum PTCSxTR A516, V520, Q535, G551 D489N, R501H 
 Rif-14 23F HD 1993 Sputum PTCSxTR A516, V520, Q535, G551  H499N 
 Rif-22 23F HD 1994 Blood PTCSxTR A516, V520, Q535, G551  H499N 
 Rif-34 23F HGM 1996 Blood PTCEClSxTR A516, V520, Q535, G551  M488I, H499Y 
 Rif-35 23F HGM 1996 Blood PTCEClSxTR A516, V520, Q535, G551  M488I, H499Y 
 Rif-36 23F HGM 1996 Blood PTCEClSxTR A516, V520, Q535, G551  M488I, H499Y 
 Rif-38 23F HGM 1996 Blood PTCEClSxTR A516, V520, Q535, G551  M488I, H499Y 
 Rif-39 23F HGM 1996 Pus PTCEClSxTR A516, V520, Q535, G551  M488I, H499Y 
 Rif-63 23F HD 2001 Eye PTCEClSxTR A516, V520, Q535, G551  L506S 
 Rif-75 23F HUB 1995 Sputum PTEClSxTR A516, V520, Q535, G551, 
S498  
H499N 
 Rif-76 23F HUB 1997 Sputum PTCSxTR A516, V520, Q535, G551  H499Y 
Spain6B-2 Rif-40 6B HD 1996 Sputum PTCR A516, V520, Q535, G551 H499Y 
 Rif-42 6B HGM 1997 BAL PTEClSxTR I468, Q535  Q150R 
 Rif-18 6B HD 1994 Sputum PTEClR I468, Q535  D489G, L506V 
 Rif-19 6B HD 1994 Blood PTEClR I468, Q535  D489G, L506V 
 Rif-30 6B HD 1995 Blood PTEClR I468, Q535  D489G, L506V 
 Rif-17 6B HUB 1994 Sputum PTCEClSxTR I468, Q535  D489N, P537S 
 24
 Rif-23 6B HUB 1995 Sputum PTCEClSxTR I468, Q535  H499Y 
 Rif-53 6B HD 1999 Sputum PTCEClSxTR I468, Q535 H499Y 
 Rif-13 6B HCA 1993 BPS PTCSxTR  Y589F, I608V, 
I624V, N669D, 
Q671K, H499N, 
Spain9V-3 Rif-55 14g HCA 2000 Pleural  PSxTR I468, Q535,  D489V 
 Rif-1 9V HD 1990 Sputum PSxTR I468, Q535,  H499Y 
Spain14-5 Rif-15 14 HD 1993 Sputum PTCEClSxTR  Y589F, H499N,  
 Rif-16 14 HD 1993 Sputum PTCEClSxTR  Y589F, H499N,  
Clone Ch Rif-2 19F HUB 1991 Sputum PTSxTR A474, V520, Q535,  S481P, H499Y 
 Rif-3 19F  1991 Sputum PTSxTR A474, V520, Q535,  D489V 
 Rif-12 19F  1999 Eye PTCEClSxTR A474, V520, Q535,  H499Y 
 Rif-28 19F  1995 Sputum PCSxTR A474, V520, Q535,  H499N 
 Rif-37 19F  1996 Sputum PTEClSxTR A474, V520, Q535,  H499N 
 Rif-31 19F  1995 Blood PTCSxTR  Y589F, D489V 
 1 
a PFGE, pulse-field gel electrophoresis SmaI patterns.  2 
b HD, Hospital de Donostia; HUB, Hospital Universitario de Bellvitge; HCA, Hospital Central de 3 
Asturias; HGM, Hospital Gregorio Marañón.  4 
c BAL, bronchial alveolar wash specimen; BPS, bronchial protected catheter brush specimen.  5 
d P, resistant to penicillin (MIC 0.12-4 µg/ml); T, resistant to tetracycline (MIC ≥4 µg/ml); C, 6 
resistant to chloramphenicol (MIC ≥8µg/ml); E, resistant to erythromycin (MIC ≥0.5 µg/ml); Cl, 7 
 25
resistant to clindamycin (MIC ≥0.5 µg/ml); SxT, resistant to trimethropin-sulfamethoxazole 1 
(MICs ≥ 4/ 76 µg/ml), R, resistant to RIF (MIC ≥ 4 µg/ml). 2 
e RpoB regions sequenced were L42-V175 and Q464-T700. Nucleotide polymorphisms are 3 
indicated by the residue number, changes observed were: I468 (ATT instead ATC); A474 (GCG 4 
instead GCA); A516 (GCT instead GCC); V520 (GTA instead GTG); Q535 (GAG instead 5 
GAA); G551 (GGT instead GGA), and S498 (TCA instead TCT). 6 
f Residue changes involved in RIF resistance are showed in boldface, and double-underlining 7 
indicates that the residue is located in a gene with a mosaic structure.  8 
g Capsular switching. 9 
h C, PFGE type related to serotype 19F with MLST 89. 10 
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TABLE 3. Relationship between RIF MICs and amino acid changes in RpoB in 53 non-1 
recombinant RIF-resistant isolatesa 2 
RpoB change at clusters: 
N I II III 
No 
isolates
Isolate or transformant strain  Rifampicine 
MIC (µg/ml )
Q150R     3 Rif-42, -61, -67 4-8 
     TQ150R/Rif-42 2 
 S481P   1 Rif-26 8 
     TS481P/Rif-59  4 
 S482P   1 Rif-10  32 
     TS482P/Rif-10 16 
 Q486K   1 Rif-33 64 
     TQ486K/Rif-33 32 
 Q486L   1 Rif-8  128 
     TQ486L/Rif-8 32 
 D489V   2 Rif-3, -55   128 
     TD489V/Rif-31 32 
 S495F   2 Rif-51, -68  16-32 
     TS495F/Rif-51 32 
 H499L   1 Rif-29  64 
     TH499L/Rif-29 16 
 H499N   11 Rif-9, -14, -22, -28, -32, -37, -45, -49,
-58, -60, -75 
8-16 
 
     TH499N/Rif-9  8 
 27
 H499S   2 Rif-69, -71  64 
     TH499S/Rif-69  16 
 H499Y   12 Rif-1, -12, -23, -40, -50, -53, -62, -64,
-66, -70, -74, -76 
128 
     TH499Y/Rif12  32 
 L506S   2 Rif-57, -63  8-16 
     TL506S/Rif-57 8 
Q150R   V638G 1 Rif-52 4 
 S481P, S485P   1 Rif-59  128 
     TS481P, S485P/Rif-59 32 
 S481P, H499Y   1 Rif-2 512 
     TS481P, H499Y/Rif-2 128 
 M488I, H499Y   5 Rif-34, -35, -36, -38, -39 512 
     TM488I, H499Y/Rif-34 256 
 D489G, L506V   3 Rif-18, -19, -30 16-32 
     TL506V/Rif-18 16 
     TD489G, L506V/Rif-18 16 
 D489N,R501H   1 Rif-7  32 
     TD489N, R501H/Rif-7 16 
  D489N P537S  1 Rif-17  16 
     TD489N, P537S /Rif-17 16 
 H499Y N547S  1 Rif-11 256 
     TH499Y, N547S /Rif-11 64 
 28
 1 
a Transformant strains (T) are R6-derivatives that carry the indicated mutations from the 2 
indicated donor isolates. For instance, TQ150R/Rif-42 carries the Q150R change of isolate Rif-42.  3 
Y
V         S
L  N         N      S
R          PP  PK IG     F   L H    V          S         S
▼ ▼▼ ▼▼ ▼▼ ▼ ▼ ▼ ▼ ▼ ▼
SPN 145-RIIVSQ-150  478-FFGSSQLSQFMDQHNPLSELSHKRRLSALGPGG-510  535-ETPEGPNIGLINNL-548 
SAU   132-RVIVSQ-137  460-FFGSSQLSQFMDQANPLAELTHKRRLSALGPGG-492  517-ETPEGPNIGLINSL-530 
MTB 173-RVVVSQ-178  429-FFGTSQLSQFMDQNNPLSGLTHKRRLSALGPGG-462  487-ETPEGPNIGLIGSL-500 
ECO   143-RVIVSQ-148  505-FFGSSQLSQFMDQNNPLSEITHKRRISALGPGG-537  562-ETPEGANIGLINSL-575 
TAQ   133-RVIVSQ-138  385-FFSRSQLSQFKDETNPLSSLRHKRRISALGPGG-417  442-ETPEGPNIGLINSL-455 





























CODON       4444444444444444555555555555555555555 55555555555  5555555 555
NUMBER      6666777777888999000111122223444455555 55556667777  7777888 999
5668012345139239167256805895025901234 56890680123  4568239 012
POSITION    33333333313313313333333333333333333313333313323312333333323333
SPN R6      TCTCTAATAGAGGCGCCAATTCTGCTTATCCATCACTGCATTGGCAATGTTCGCTATATTAT
Rif-31      ............G...T..A.A.AT..G..........TGA.........A.A.C..T...G
Rif-15,-16  C.......T.....AA...A.T.A.CCG.T........................C.CT..GG
Rif-25      C.......T.....AA...A.T...CAG..T...G...T.......G.....CTC..T...A
Rif-13      .......A.....T.A...A.T....CG..T.A......G....T......T.TC.CTC..G
Rif-56      ...T.C..G.....AA..GACT.A.CCG..T....T...G...........T..C.CT...A
Rif-24      ........G.....AA...A.TCA.CCG..........TG..............C..T...A
SMI 12261   ........G.....A..GGA.T.A.C.G...............A.......T..C.CT...A
SOR 10557   C.C.A...G.......T..A...AT..G....ATT....GA.....T...A.A.C.CTC..G
SOR 11427   C.......G....TA....A.T.AT..G......G....G......T...A.A.C.CT...G
Rif-65      CTC.AGTGGATA..AAT......A....A..T....CC.G.CA..CTAAAATC..TC.CA.G
CODON       555  5 56 6666666666666  6  666666666666666 6 666 6666666 6667
NUMBER      999  9 90 0000001111222  2  223335556666677 7 888 8888889 9990
457  8 90 1236783689023  4  670127893568901 4 013 4567891 4560
POSITION    33123133233333313333331231233333333333331313233323333333133333
SPN R6      TCCGTCGTAATACGGACCAGTTAATATTCCTAAACTGGATATCGACACCACCTTTGGGGTTT
Rif-31      ..............................................................
Rif-15,-16  C.....T......A.....................C...C...A...T.....AAT......
Rif-25      .T............AG..............A....C.T....GA.........AAT......
Rif-13      C.....TC......AG........CG....AT...C....GAAA........C.........
Rif-56      .T.........TT..G....CAG.AG.A.....T.C....GAA.....T.............
Rif-24      .T.A........A.AG.....AG.AG.G..G..T.C..T.GAAA....T.TTC..T.T...A
SMI 12261   .T..........A.AG.....G...G....A....C.A....AA.........AA.....CC
SOR 10557   C.....TC..CTT.AG.....AG.AG.G..G..T.C....GAAA......TTC..T.T....
SOR 11427   ......TC.GCTT.AGT.G..AG.AG.G..G..T.C..T.GAAA..GT...TC..C.G...A
Rif-65      C.AAAT.CC...TAAG.T.A.ATCA.GCTT.TTTTCA...GAAATT...T..CAATATAC.C
B 
CODON       444455555666666666
NUMBER      789967789002267789  RIF MIC  TYPE
597900397083491431  (µg/ml)
SPN R6      VDLHVEVYREININQYAV  0.015
Rif-31      .V.....F..........    512     19F
Rif-15,-16  ...N...F..........   8-16     14
Rif-25      ...N...F..V.V.K...      8     NT
Rif-13      ...N...F..V.VDK...     16      6B
Rif-56      ...N...F..VEVDK.V.     64     14
Rif-24      ...N...FH.VEVDK.V.     64     23A
SMI12261    .......F..V.V.K...  0.015 
SOR10557    .......F..VEVDK...  0.015
SOR11427    .......F..VEVDK...  0.015
Rif-65      I.VNIAK.KAVSSDKF.I 16      9V
T700



























S. oralis NCTC 11427
Rif31
S. oralis ATCC 10557
Rif38(Spain23F-1)
Rif3(Clone C)
S. pneumoniae R6
Rif55(Spain9V-3) 
97
99
0.02 
